Stay Up to Date
Breaking News,
Updates, & More
Click Here to

TOP - November 2016, Vol 9, No 4

Chicago, IL—A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML), according to results of a phase 3 trial presented at the American Society of Clinical Oncology 2016 Annual Meeting.

Page 3 of 3
Results 21 - 21 of 21